<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332552</url>
  </required_header>
  <id_info>
    <org_study_id>115040</org_study_id>
    <nct_id>NCT01332552</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects</brief_title>
  <official_title>A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2485852 is a Hepatitis C NS5B site IV non-nucleoside polymerase inhibitor being developed
      for the treatment of chronic HCV infection. HBI115040 is the first administration of
      GSK2485852 in humans to establish the initial safety, tolerability, pharmacokinetic, and
      antiviral profile. The study design is a fusion of single and repeat dosing cohorts in HCV
      infected subjects to evaluate the safety, pharmacokinetics, and antiviral activity of
      GSK2485852.

      HBI115040 describes a Phase I, randomized, double-blind, placebo-controlled, dose escalation
      fusion study to determine the safety, tolerability, pharmacokinetic, and antiviral profile of
      GSK2485852 in single doses (Part 1), repeat doses (Part 2), and ritonavir co-administration
      (Part 3) in chronically infected HCV subjects. The study will also explore the effect of a
      moderate (30%) fat meal on pharmacokinetic endpoints in HCV subjects in Part 1.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to unfavorable human pharmacokinetic properties
  </why_stopped>
  <start_date type="Actual">January 14, 2011</start_date>
  <completion_date type="Actual">April 6, 2011</completion_date>
  <primary_completion_date type="Actual">April 6, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety parameters: adverse events; telemetry; absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs (blood pressure, heart rate), and electrocardiogram (ECG) parameters</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2485852 PK parameters following single dose administration: AUC(0-inf), AUC(0-t), AUC(0-24), Cmax, tmax, C24, t1/2, tlag, and CL/F</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK2485852 PK parameters following repeat dose administration: AUC(0-τ), Cτ, Cmax, tmax, t1/2, and CL/F</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV RNA viral load reduction from baseline</measure>
    <time_frame>24 to 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV RNA change from baseline to nadir</measure>
    <time_frame>up to 72 h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of HCV viral load at baseline, during dosing with GSK2485852, and &gt; or = 14 days after GSK2485852 dosing</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 PK parameters: AUC(0-24), Cmax, tmax and tlag following a single dose with and without moderate fat/calorie meal.</measure>
    <time_frame>24 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 accumulation ratio (R)</measure>
    <time_frame>72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 time invariance in non-food cohorts</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK2485852 dose proportionality after single or repeat dosing in non-food cohorts</measure>
    <time_frame>up to 72 h</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: GSK2485852 + Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 70 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single dose</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Repeat dose, once daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>Repeat dose, twice daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 420 mg</intervention_name>
    <description>Repeat dose, TIDfor 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 630 mg</intervention_name>
    <description>Repeat dose, twice daily for 3 days</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 70 mg + Ritonavir 100mg</intervention_name>
    <description>single dose, day 1</description>
    <arm_group_label>Part 1: Single dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 210 mg + Ritonavir 100mg</intervention_name>
    <description>single dose, day 1</description>
    <arm_group_label>Part 2: Repeat dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2485852 210 mg +Ritonavir 100mg</intervention_name>
    <description>single dose daily for 3 days</description>
    <arm_group_label>Part 3: GSK2485852 + Ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A subject will be eligible for inclusion in this study only if all of the following
             criteria apply: Healthy as determined by a responsible and experienced physician,
             based on a medical evaluation including medical history, physical examination,
             laboratory tests and cardiac monitoring (i.e., ECG), including no cardiac, pulmonary,
             hepatic, biliary, gastrointestinal, or renal disorders, or cancer within the past 5
             years.

          -  Males or females between 18 and 65 years of age inclusive, at the time of signing the
             informed consent.

          -  A female subject is eligible to participate if she is of non-childbearing potential.

          -  Body weight &gt; or = 50 kg (110 lbs.) for men and &gt; or = 45 kg (99 lbs.) for women and
             BMI between 18.5-35.0 kg/m2 inclusive will be allowed.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  AST, ALT, and alkaline phosphatase &lt;3.0xULN and bilirubin &lt;1.5xULN (isolated bilirubin
             &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Average QTcB or QTcF &lt; 450 msec; or QTcB or QTcF &lt; 480 msec in subjects with Bundle
             Branch Block.

          -  Treatment naive chronically infected HCV subjects, defined as infection for &gt;6 months
             and no prior HCV therapy, with an HCV RNA viral load of greater than 100,000 IU/mL and
             HCV genotype 1a or 1b. HCV subjects with mixed genotypes are not eligible for the
             study.

          -  Positive for HCV RNA and anti-HCV antibody at the time of screening AND positive for
             anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening; OR
             Positive for HCV RNA and anti-HCV antibody at the time of screening AND liver biopsy
             within three years prior to screening indicating the absence of cirrhosis.

        Exclusion Criteria:

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Subject is mentally or legally incapacitated.

          -  A positive pre-study Hepatitis B surface antigen or HIV antibody within 3 months of
             screening.

          -  A positive pre-study drug/alcohol screen.

          -  History of regular alcohol consumption within 6 months of the study.

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior
             to the first dose of study medication.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer). Exposure to more than four new
             investigational products within 12 months prior to the first dosing day.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication,

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day period.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Holter monitoring shows one or more of the following: Any symptomatic arrhythmia
             (except isolated extra systoles); Sustained cardiac arrhythmias (such as atrial
             fibrillation or flutter, SVT (&gt;10 consecutive beats)); Sustained tachycardia &gt;150
             beats per minute; Non-sustained or sustained ventricular tachycardia (defined as &gt;3
             consecutive ventricular ectopic beats); Any conduction abnormality (including but not
             specific to left or right complete bundle branch block, AV block [2nd degree or higher
             in an awake subject], WPW syndrome, other pre-excitation syndromes); Symptomatic sinus
             pause or sinus pause &gt;3 seconds - unless patient is straining, vomiting, or having
             some other type of hypervagal response; 300 or more supraventricular ectopic beats in
             24 hours; 250 or more ventricular ectopic beats in 24 hours; Ischemia, diagnosed by a
             sequence of ECG changes that include flat or downsloping ST-segment depression &gt;0.1
             mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each
             episode of ischemia must be separated by a minimum duration of at least 1 minute,
             during which the ST segment returns back to baseline (1x1x1 rule).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/115040?search=study&amp;search_terms=115040#rs</url>
    <description>Results for study 115040 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>First administration to human</keyword>
  <keyword>antiviral activity</keyword>
  <keyword>safety</keyword>
  <keyword>hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115040</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

